Scisparc

Scisparc EBIT Margin

The EBIT Margin (Operating Margin) of Scisparc (SPRC) as of Nov 12, 2026 is -1,022.08 %. In the previous year, EBIT Margin (Operating Margin) was -560.18 % — a change of 82.45% (lower).

EBIT Margin

-1,022.08 %

YoY

82.45%

Last updated:

EBIT Margin (Operating Margin) of Scisparc is 2025 -1,022.08 % . EBIT Margin (Operating Margin) of Scisparc was 2024 -560.18 % . It decreases by 82.45% lower compared to the previous year.

Scisparc's operating (EBIT) margin stands at -1,022.1%, down from -539.6% several years earlier.

The Scisparc EBIT Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Margin
Date
EBIT Margin
Jan 1, 2018
-1,159.19 USD
Jan 1, 2019
-824.90 USD
Jan 1, 2020
-598.73 USD
Jan 1, 2021
-539.57 USD
Jan 1, 2022
-547.88 USD
Jan 1, 2023
-200.52 USD
Jan 1, 2024
-560.18 USD
Jan 1, 2025
-1,022.08 USD
The Scisparc EBIT Margin history
YEAREBIT MarginYoY
-1,022.08 %+82.45%
-560.18 %+179.36%
-200.52 %-63.40%
-547.88 %+1.54%
-539.57 %-9.88%
-598.73 %-27.42%
-824.90 %-28.84%
-1,159.19 %-1.89%
-1,181.52 %+63,469.49%
-1.86 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Scisparc Stock analysis

What does Scisparc do? SciSparc Ltd develops cannabinoid-based pharmaceuticals including THX-110 for Tourette syndrome, Obstructive Sleep Apnea, and pain; THX-130 for Mild Cognitive Impairment and Traumatic Brain Injury; THX-150 for infectious diseases; and THX-160 for pain. The company monetizes through drug development programs targeting specific medical conditions, with pharmaceutical companies and research institutions as primary buyers of these development assets. The firm's revenue streams derive from licensing agreements and partnerships with biopharmaceutical entities seeking to advance cannabinoid-based therapies for unmet medical needs. SciSparc focuses on repurposing Dronabinol into multiple therapeutic applications, creating a diversified portfolio of drug candidates. Its products target neurological disorders, sleep disorders, and infectious diseases, appealing to healthcare providers and patients requiring innovative treatments. The company's business model relies on generating revenue through the sale of development-stage drug assets to larger pharmaceutical firms rather than direct patient sales. The firm's pipeline includes four distinct drug candidates, each addressing different medical conditions. THX-110 targets Tourette syndrome, Obstructive Sleep Apnea, and pain; THX-130 addresses Mild Cognitive Impairment and Traumatic Brain Injury; THX-150 targets infectious diseases; and THX-160 focuses on pain management. These assets are marketed to biopharmaceutical companies as potential additions to their therapeutic portfolios. Scisparc is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Scisparc stock

EBIT Margin (Operating Margin) of Scisparc is -1,022.08 % in 2025.

EBIT Margin (Operating Margin) of Scisparc changed from -560.18 % to -1,022.08 %, representing a 82.45% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT Margin (Operating Margin) Scisparc since 2006 – with annual values, charts, and detailed analysis.

EBIT Margin measures operating profitability as a percentage of revenue. It shows how much profit a company makes from operations before interest and taxes.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBIT Margin (Operating Margin)'s Scisparc with sector peers and the industry average to assess whether it is attractive.

To evaluate EBIT Margin (Operating Margin)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBIT Margin (Operating Margin).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Scisparc

All Key Metrics — Scisparc